Hyperhydration is typically used along with high-dose melphalan in patients undergoing stem cell transplantation. However, the evidence behind this practice is limited and the dosage administered to patients needs refining. In this interview, Midori Nakagaki, BPharm, MSc, from the Royal Brisbane Hospital, Brisbane, Australia, discusses the findings of her groups study retrospectively comparing patients response with hyperhydration vs. without hyperhydration. Midori emphasizes the advantages in reducing dosage, namely easing the workload for healthcare professionals and minimizing the pressures on patients. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting in Lisbon, Portugal.